DOI:
10.1055/s-00000077
Seminars in Thrombosis and Hemostasis
LinksClose Window
References
Kubitza D, Becka M, Zuehlsdorf M, Mueck W.
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.
J Clin Pharmacol 2007;
47 (2) 218-226
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.